These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1045 related items for PubMed ID: 19733719

  • 1. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB.
    Am J Cardiol; 2009 Sep 15; 104(6):829-34. PubMed ID: 19733719
    [Abstract] [Full Text] [Related]

  • 2. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM.
    Am J Cardiol; 2005 Dec 15; 96(12):1674-80. PubMed ID: 16360356
    [Abstract] [Full Text] [Related]

  • 3. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ.
    J Am Osteopath Assoc; 2002 Jul 15; 102(7):377-84. PubMed ID: 12138952
    [Abstract] [Full Text] [Related]

  • 4. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.
    Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM.
    J Womens Health Gend Based Med; 2001 Dec 15; 10(10):971-81. PubMed ID: 11788107
    [Abstract] [Full Text] [Related]

  • 5. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, LIPID Study Investigators.
    Eur Heart J; 2004 May 15; 25(9):771-7. PubMed ID: 15120888
    [Abstract] [Full Text] [Related]

  • 6. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT.
    N Engl J Med; 1990 Nov 08; 323(19):1289-98. PubMed ID: 2215615
    [Abstract] [Full Text] [Related]

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 08; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM.
    JAMA; 1998 May 27; 279(20):1615-22. PubMed ID: 9613910
    [Abstract] [Full Text] [Related]

  • 9. [Statins in primary prevention of coronary heart disease].
    Paulweber B.
    Wien Med Wochenschr; 1999 May 27; 149(5-6):129-38. PubMed ID: 10408004
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
    deGoma EM, Leeper NJ, Heidenreich PA.
    J Am Coll Cardiol; 2008 Jan 01; 51(1):49-55. PubMed ID: 18174036
    [Abstract] [Full Text] [Related]

  • 11. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 12. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM.
    Atheroscler Suppl; 2007 Aug 01; 8(2):3-8. PubMed ID: 17588826
    [Abstract] [Full Text] [Related]

  • 13. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
    Forti N, Ramires JA.
    Arq Bras Cardiol; 1991 Sep 01; 57(3):253-61. PubMed ID: 1824203
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508
    [Abstract] [Full Text] [Related]

  • 15. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS.
    Am Heart J; 2006 Mar 15; 151(3):556-63. PubMed ID: 16504615
    [Abstract] [Full Text] [Related]

  • 16. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 15; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 17. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.
    Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM.
    Am Heart J; 2006 Mar 15; 151(3):755.e1-755.e6. PubMed ID: 16504648
    [Abstract] [Full Text] [Related]

  • 18. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
    Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM, Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators.
    Circulation; 2002 Apr 16; 105(15):1776-9. PubMed ID: 11956118
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.
    Arterioscler Thromb Vasc Biol; 2008 Jun 16; 28(6):1172-8. PubMed ID: 18356553
    [Abstract] [Full Text] [Related]

  • 20. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS.
    Eur Heart J; 2000 Oct 16; 21(19):1627-33. PubMed ID: 10988016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.